History

Vanda is based in Washington DC and was found in 2003. Vanda (VNDA) is a NASDAQ traded company since 2006. Vanda is founded on the principles of the application of advanced scientific methodology in the development of therapeutics. In 2009 Vanda obtained its first FDA approval for Fanapt® (iloperidone) an atypical antipsychotic for the treatment of patients with schizophrenia. In 2014 we obtained FDA approval for Hetlioz® (tasimelteon) a first in class drug for the treatment of patients with Non24 Hour Sleep Wake Disorder (Non24), which was followed by an EMA approval in the EU in 2015. Vanda has also added to its pipeline the neurokinin 1 receptor (NK1R) antagonist tradipitant which is being tested in clinical studies for the treatment of patients with atopic dermatitis and gastroparesis. Vanda is also pursuing the development of tasimelteon for the treatment of patients with Smith Magenis Syndrome (SMS) and Jet Lag Disorder (JLD). Iloperidone is also being developed as a one month injectable for the treatment of schizophrenia. Our oncology program consists of Trichostatin A (TSA) for the treatment of patients with hematologic malignancies who have failed on prior treatments. The development of our assets is further enhanced by the application of modern genetic technologies in pursuit of genetic factors that can further enhance the efficacy and safety of our products.